This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (80)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Pathology & Laboratory Medicine  • Alert me on articles by topic  Social Bookmarking   What's this?

Yael C. Cohen, MD; Benjamin Djulbegovic, MD; Orna Shamai-Lubovitz, MD; Benjamin Mozes, MD

Arch Intern Med. 2000;160:1630-1638.

Background  No firm data are available on the natural history of idiopathic thrombocytopenic purpura (ITP) or on mortality rates or frequency of major bleeding episodes associated with this condition. The disease is thought to have a relatively benign course, despite the frequent occurrence of very low platelet counts. This prevailing conception often guides therapeutic decisions.

Objective  To estimate the bleeding risk of ITP involving persistent low platelet counts (<30 x 10⁹/L) and its impact on prognosis.

Design  Age-adjusted bleeding risk was derived from a pooled analysis of ITP clinical series based on a systematic literature search. The risk estimate was incorporated into a Markov model to determine its impact on prognosis.

Results  Seventeen case series complied with inclusion criteria, including 1817 patients with ITP. There were 49 cases of fatal hemorrhage over an estimated 1258 to 3023 patient-years at risk. The rate of fatal hemorrhage before age adjustment was estimated at between 0.0162 and 0.0389 cases per patient-year. Age-adjusted rates were 0.004, 0.012, and 0.130 cases per patient-year for age groups younger than 40, 40 to 60, and older than 60 years, respectively. Predicted 5-year mortality rates ranged from 2.2% for patients younger than 40 years to 47.8% for those older than 60 years. A 30-year-old woman remaining thrombocytopenic due to ITP was predicted to lose 20.4 years (14.9 quality-adjusted life years) of her potential life expectancy. At age 70, predicted loss was 9.4 years (5.0 quality-adjusted life years).

Conclusions  Idiopathic thrombocytopenic purpura with persistent low platelet counts carries a grave prognosis. Therefore, an active therapeutic approach in the clinical management of affected patients should be considered. In view of the significant potential implications of the model results, we call for initiating a well-designed prospective inception cohort study of patients with ITP.

From the Gertner Institute for Epidemiology and Health Policy Research, The Chaim Sheba Medical Center, Tel Hashomer, Israel (Drs Cohen, Shamai-Lubovitz, and Mozes); and the H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Division of Bone Marrow Transplant, Tampa (Dr Djulbegovic).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Rodeghiero et al.
Blood 2009;113:2386-2393.
ABSTRACT | FULL TEXT  

Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura
Pruemer
Am J Health Syst Pharm 2009;66:S4-S10.
ABSTRACT | FULL TEXT  

New options after first-line therapy for chronic immune thrombocytopenic purpura
Burzynski
Am J Health Syst Pharm 2009;66:S11-S21.
ABSTRACT | FULL TEXT  

Pharmacodynamics and Pharmacokinetics of AMG 531, a Thrombopoiesis-Stimulating Peptibody, in Healthy Japanese Subjects: A Randomized, Placebo-Controlled Study
Kumagai et al.
J Clin Pharmacol 2007;47:1489-1497.
ABSTRACT | FULL TEXT  

Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP)
Boruchov et al.
Blood 2007;110:3526-3531.
ABSTRACT | FULL TEXT  

Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
Arnold et al.
ANN INTERN MED 2007;146:25-33.
ABSTRACT | FULL TEXT  

ITP in the 21st Century
Beardsley
ASH Education Book 2006;2006:402-407.
ABSTRACT | FULL TEXT  

How I treat idiopathic thrombocytopenic purpura (ITP)
Cines and Bussel
Blood 2005;106:2244-2251.
FULL TEXT  

Long-term outcomes in adults with chronic ITP after splenectomy failure
McMillan and Durette
Blood 2004;104:956-960.
ABSTRACT | FULL TEXT  

Management of Immune Thrombocytopenic Purpura in Adults
Stasi and Provan
Mayo Clin Proc. 2004;79:504-522.
ABSTRACT  

Immune Thrombocytopenic Purpura
Cines and Blanchette
NEJM 2002;346:995-1008.
FULL TEXT  

The natural history of refractory idiopathic thrombocytopenic purpura
Djulbegovic et al.
Blood 2001;98:2282-2283.
FULL TEXT  

Morbidity and mortality in adults with idiopathic thrombocytopenic purpura
Portielje et al.
Blood 2001;97:2549-2554.
ABSTRACT | FULL TEXT